

## Rehabilitation & Entitlements Policy Group

# SOP Bulletin No. 164

11 March 2013

**THE FOLLOWING RMA SOPS ARE TO TAKE EFFECT ON 13 MARCH, 2013**

<b>New SOPs</b>	<b>Essential thrombocythaemia Primary myelofibrosis</b>
<b>Revocations &amp; Replacements</b>	<b>Polycythaemia vera Seborrhoeic dermatitis</b>
<b>Amendments</b>	<b>Hypopituitarism</b>

### NOTEWORTHY FEATURES

<b>Essential thrombocythaemia</b>	<b>New – 15 &amp; 16 of ‘13</b>
<ul style="list-style-type: none"><li>•</li></ul>	
<b>Primary myelofibrosis</b>	<b>New – 17 &amp; 18 of ‘13</b>
<ul style="list-style-type: none"><li>• These two SOPs, plus the revised polycythaemia vera SOP, are the outcomes from the RMA’s investigation into “JAK-related myeloproliferative disorders”.</li><li>• These rare conditions are classified as myeloproliferative neoplasms, but they are not malignancies.</li><li>• There are no known causes for either condition. The SOPs have “inability” factors only.</li><li>• There are numerous secondary causes of both myelofibrosis and thrombocythaemia that are excluded from these SOPs.</li></ul>	
<b>Polycythaemia vera</b>	<b>Revocation – 11 &amp; 12 of ‘13</b> Replaces 78 and 79 of ‘99 as amended by 11 & 12 of ‘01 and 30 of ‘05
<ul style="list-style-type: none"><li>• Polycythaemia vera belongs to the same group of chronic non-malignant myeloproliferative neoplasms as the above two conditions. It again has no known causes.</li><li>• The new version of this SOP has a revised definition and formatting changes, but no new or amended factors.</li></ul>	
<b>Seborrhoeic dermatitis</b>	<b>Revocation – 13 &amp; 14 of ‘13</b> Replaces 21 and 22 of ‘05
<ul style="list-style-type: none"><li>• There has been a change in the RH SOP to the definition for specified psychiatric diseases that applies to the inability to maintain personal hygiene factor. Alcohol dependence has been added to the specified list of psychiatric diseases.</li></ul>	

- There are new RH only factors for solid organ transplant and for treatment with erlotinib or interferon alpha (both cancer chemotherapy agents).

**Hypopituitarism****Amendment – 19 & 20 of '12**

Amends 76 and 77 of '09

- The amendment is to the definition of “infiltration of the pituitary gland or hypothalamus due to a specified disorder. The previous incorrect reference to “adrenal gland” has been changed to “pituitary gland or hypothalamus”. As well, two conditions, eosinophilic granuloma and giant-cell granuloma, have been added to the list of specified disorders in both the RH and BOP SOPs.

**Contact Officers for this bulletin:**

Dr Jon Kelley	48412
Dr Edwin Nicoll	48583

